Strs Ohio Has $363,000 Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Strs Ohio increased its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 30.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,000 shares of the company’s stock after acquiring an additional 2,100 shares during the period. Strs Ohio’s holdings in BridgeBio Pharma were worth $363,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Handelsbanken Fonder AB grew its position in shares of BridgeBio Pharma by 4.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 24,750 shares of the company’s stock valued at $653,000 after acquiring an additional 1,000 shares during the period. Emerald Advisers LLC raised its position in shares of BridgeBio Pharma by 44.8% during the 3rd quarter. Emerald Advisers LLC now owns 694,000 shares of the company’s stock valued at $18,301,000 after buying an additional 214,875 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of BridgeBio Pharma by 26.5% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 500,254 shares of the company’s stock valued at $13,192,000 after buying an additional 104,714 shares in the last quarter. Assetmark Inc. purchased a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at $53,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in shares of BridgeBio Pharma by 4.1% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 87,981 shares of the company’s stock valued at $2,320,000 after purchasing an additional 3,494 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of BridgeBio Pharma in a report on Monday, March 4th. BMO Capital Markets assumed coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 31st. They set a “market perform” rating and a $37.00 target price on the stock. Cantor Fitzgerald lifted their target price on shares of BridgeBio Pharma from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, March 19th. Raymond James assumed coverage on shares of BridgeBio Pharma in a research note on Thursday, March 21st. They set an “outperform” rating and a $45.00 target price on the stock. Finally, Citigroup lifted their target price on shares of BridgeBio Pharma from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $47.82.

Insider Transactions at BridgeBio Pharma

In other news, Director Randal W. Scott sold 2,500 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $34.00, for a total value of $85,000.00. Following the completion of the sale, the director now owns 6,500 shares in the company, valued at approximately $221,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.52% of the company’s stock.

BridgeBio Pharma Stock Up 2.3 %

BBIO stock opened at $24.88 on Monday. BridgeBio Pharma, Inc. has a 52 week low of $12.75 and a 52 week high of $44.32. The company has a fifty day simple moving average of $29.42 and a two-hundred day simple moving average of $31.79. The firm has a market capitalization of $4.37 billion, a P/E ratio of -6.31 and a beta of 1.03.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, February 22nd. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.09). The firm had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $4.78 million. The company’s revenue was down 8.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.92) EPS. As a group, analysts anticipate that BridgeBio Pharma, Inc. will post -3.09 EPS for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.